Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Immunotherapy
Clinical trial register · China

Immunotherapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 17 Beijing 15 Shanghai 13 Wuhan 7 Chengdu 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University6 West China Hospital5 Fudan University5 Cancer Institute and Hospital, Chinese Academy of Medical Sciences4 Shandong Cancer Hospital and Institute3
Site location
Guangzhou17 Beijing15 Shanghai13 Wuhan7 Chengdu6
All 32 locations
Target enrolment
to

Immunotherapy trials in China

89 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Tao Zhang
Phase 2
144
Wuhan
2026-11-01
Not yet open
Tianjin Medical University Second Hospital
Phase 2
150
Tianjin, Xingtai
2026-10-20
Recruiting
Shandong Cancer Hospital and Institute
Phase 3
180
Jinan
2026-08-15
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
NCT07894458Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
Peking University People's Hospital
Not applicable
100
Beijing
2026-08-12
Not yet open
West China Hospital
Phase 2
66
Chengdu
2026-08
Recruiting
Tao Zhang
Phase 3
444
Wuhan
2026-05-15
Recruiting
Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
NCT07668037Non-Small Cell Carcinoma of Lung, Immunotherapy, Advanced Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2026-05-01
Recruiting
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
NCT07538479Solid Tumors, Solid Malignancies, Cold Exposure, Immunotherapy
West China Hospital
Phase 1
24
Chengdu
2026-04-20
Recruiting
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
NCT06768931Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
Sun Yat-sen University
Phase 2
192
Lanzhou, Dongguan, Guangzhou, Zhanjiang, Zigong
2026-04-01
Recruiting
Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
NCT07565532Small Cell Lung Cancer ( SCLC ), Radiotherapy, Immunotherapy, Personalized Cancer Treatment
Shanghai Chest Hospital
Observational
500
Shanghai
2026-04-01
Recruiting
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Not yet open
Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)
NCT07396116Soft Tissue Sarcoma (STS), Retroperitoneal Sarcoma, Immunotherapy, Radiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
28
Beijing
2026-02-12
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
NCT07458529Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
Seventh Medical Center of PLA General Hospital
Phase 2
50
Beijing
2026-02-10
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
76
Guangzhou
2026-01-01
Recruiting
Tao Zhang
Phase 2
25
Wuhan
2026-01-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
90
Guangzhou
2025-12-01
Recruiting
Obstetrics & Gynecology Hospital of Fudan University
Phase 2
20
Shanghai
2025-12
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
39
Shijiazhuang
2025-09-28
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2025-08-11
Not yet open
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xi’an, Hangzhou
2025-07-31
Not yet open
Fujian Cancer Hospital
Phase 2
44
Fuzhou
2025-07-30
Recruiting
Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
NCT07085234Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-07-30
Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
40
Chongqing
2025-07-23
Recruiting
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
NCT07359040Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
DrugsVenetocalx·Ivonescimab
Peking University People's Hospital
Observational
80
Beijing
2025-07-01
Recruiting
Chinese PLA General Hospital
Phase 2
90
Beijing
2025-07-01
Not yet open
Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer
NCT06848439Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy, Molecular Targeted Therapy
Jiangsu Cancer Institute & Hospital
Phase 2
26
Nanjing
2025-06-15
Active, closed
West China Hospital
Phase 1/2
29
Chengdu
2025-06-10
Recruiting
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
NCT06985485Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin
The First Affiliated Hospital of Soochow University
Phase 2
26
Suzhou
2025-05-17
Recruiting
Peking University People's Hospital
Observational
100
Beijing
2025-05-08
Recruiting
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
NCT07166003Lung Cancer, Non-Small Cell, Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2025-04-20
Recruiting
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Recruiting
Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
NCT06915389Gastric Cancer, Immunotherapy, Adverse Event, Metabonomics
Qinghai Red Cross Hospital
Observational
100
Xining
2025-02-22
Recruiting
Fudan University
Phase 2
27
Shanghai
2025-02-15
Recruiting
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
NCT06716619Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
DrugSerplulimab
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
32
Guangzhou
2025-02-13
Recruiting
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
NCT06964568Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
452
Shanghai
2025-02-01
Recruiting
Zhongda Hospital
Observational
332
Nanjing
2025-01-31
Not yet open
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NCT06781112TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
Weiwei Zhang
Phase 2
35
Chengdu
2025-01-20
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2025-01-07
Recruiting
Changzhi People's Hospital Affiliated to Changzhi Medical College
Observational
170
Changzhi
2025-01-01
Recruiting
Probiotics in Advanced Urothelial Carcinoma
NCT06904573Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
DrugsEnfortumab Vedotin·Disitamab Vedotin·Toripalimab·Nab-paclitaxel
Sun Yat-sen University
Phase 2
222
Guangzhou, Wuhan
2025-01-01
Recruiting
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Recruiting
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
NCT06755567Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
750
Guangzhou
2024-12-25
Active, closed
Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
NCT07046195Hypofractionated Radiotherapy, Triple Negative Breast Cancer (TNBC), Immunotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
250
Guangzhou
2024-12-11
Recruiting
jianming xu
Observational
50
Beijing
2024-12-02
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
497
Guangzhou
2024-11-30
Recruiting
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
NCT07020247Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy
West China Hospital
Phase 3
184
Chengdu
2024-11-19
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
20
Xiamen
2024-11-05
Recruiting
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
NCT06676449Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
432
Shanghai
2024-11-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
86
Wuhan
2024-11-01
Recruiting
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
NCT06702826Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
DrugCadonilimab
Rongrong Zhou
Phase 2
20
Changsha
2024-11-01
Not yet open
Fujian Cancer Hospital
Phase 2
37
Fuzhou
2024-10-01
Active, closed
Nanfang Hospital, Southern Medical University
Observational
17
Guangzhou
2024-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2024-09-01
Not yet open
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
NCT06567600Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2
43
Guangzhou
2024-09-01
Recruiting
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT06413342Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
DrugSintilimab
Zhejiang Cancer Hospital
Phase 2
191
Hangzhou
2024-06-01
Recruiting
Nutrition Impact on Immunotherapy of Cancer
NCT06500234Nutrition Disorders, Immunotherapy, Cancer, Survival, Prosthesis
Qingdao Central Hospital
Phase 3
300
Qingdao
2024-06-01
Recruiting
Hunan Province Tumor Hospital
Phase 2
78
Changsha
2024-05-29
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
DrugCardonilizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
Recruiting
Fujian Medical University Union Hospital
Phase 2
48
Fuzhou
2024-04-11
Recruiting
Shandong Cancer Hospital and Institute
Phase 2
62
Jinan
2024-04-01
Recruiting
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06037733Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-03-13
Recruiting
Sun Yat-sen University
Not applicable
112
Guangzhou
2024-03-04
Recruiting
Immunotherapy for Hepatocellular Carcinoma
NCT06241326Hepatocellular Carcinoma, Immunotherapy
The First Affiliated Hospital with Nanjing Medical University
Observational
11,000
Nanjing
2024-03-01
Recruiting
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06020430Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-02-08
Recruiting
Toripalimab Combined With Definitive CCRT for LACC Patients
NCT06256224Cervical Cancer, Chemoradiotherapy, Immunotherapy
DrugToripalimab
Ruijin Hospital
Not applicable
150
Shanghai
2024-02-02
Active, closed
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
NCT06215677Colon Cancer, Mismatch Repair Deficiency, Immunotherapy
DrugCamrelizumab
Peking Union Medical College Hospital
Phase 2
18
Beijing
2024-01-01
By invitation
Beijing Ditan Hospital
Not applicable
180
Beijing
2023-12-01
Recruiting
Shengjing Hospital
Phase 2
136
Shenyang
2023-09-26
Recruiting
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
NCT05862259Malignant Tumor, Immunotherapy, Artificial Intelligence
Xinqiao Hospital of Chongqing
Observational
120
Chongqing
2023-08-10
Recruiting
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
NCT06302062Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
DrugsAldesleukin·Serplulimab·Cyclophosphamide
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
23
Guangzhou
2023-06-06
Recruiting
Second Xiangya Hospital of Central South University
Observational
200
Changsha
2023-05-01
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
57
Guandong
2023-04-10
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 3
130
Nanjing
2023-01-31
Recruiting
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
NCT06241807IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
DrugCamrelizumab
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2022-12-02
Recruiting
The Affiliated Hospital of Xuzhou Medical University
Phase 1
20
Xuzhou
2022-12-01
Active, closed
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
NCT05621707Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
DrugVenetocalx
Shanghai Chest Hospital
Phase 2
50
Shanghai
2022-11-02
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
30
Shanghai
2022-08-03
Recruiting
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
NCT06391190Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy
RenJi Hospital
Phase 1/2
20
Shanghai
2022-01-01
Active, closed
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
NCT05176002Esophageal Neoplasm, Immunotherapy, Radiotherapy
DrugCamrelizumab
Fujian Medical University Union Hospital
Phase 1/2
25
Fuzhou
2021-11-10
Not yet open
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Active, closed
Fudan University
Phase 1/2
25
Shanghai
2021-06-09
Active, closed
Shanghai Zhongshan Hospital
Phase 2/3
294
Shanghai
2021-03-25
Recruiting
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
NCT04688801Esophageal Cancer, Gastroesophageal Cancer, Immunotherapy, Adjuvant
The Second Hospital of Shandong University
Not applicable
200
Jinan
2020-07-01
By invitation
Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer
NCT06849362Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer, Immunotherapy
DrugBevacizumab
Yue Gou
Observational
200
Changsha
2019-12-01
Recruiting
Guangdong Association of Clinical Trials
Observational
100
Guangzhou
2019-05-01
Recruiting
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
NCT06889649Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
DrugsAxitinib·JS001·Toripalimab
Peking University First Hospital
Phase 2
30
Beijing
2019-01-01
Recruiting
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
NCT03198546Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Rows per page Showing 1–89 of 89
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/immunotherapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 89 of those studies listing the condition Immunotherapy.

How many Immunotherapy trials are recruiting in China?

67 of the 89 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 12 have not yet opened recruitment, 8 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Immunotherapy), 89 studies
PhaseStudiesRecruitingShare
Phase 2402844.9%
Observational181520.2%
Not applicable9710.1%
Phase 3889%
Phase 1666.7%
Phase 1/2525.6%
Phase 2/3202.2%
Phase 4111.1%

Most active sponsors

Lead sponsors with the most studies (Immunotherapy)
Lead sponsorStudiesRecruiting
Sun Yat-sen University65
Fudan University54
West China Hospital53
Cancer Institute and Hospital, Chinese Academy of Medical Sciences43
Nanfang Hospital, Southern Medical University32
Peking University People's Hospital33
Shandong Cancer Hospital and Institute33
Tao Zhang32
The First Affiliated Hospital with Nanjing Medical University32
Fujian Cancer Hospital20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.